A placebo controlled, parallel group, randomised withdrawal study of subjects with symptoms of spasticity due to multiple sclerosis who are receiving long-term GW-1000-02 (Sativex®).
What it found
We found no results in the registry or in papers.
What was tested
Treatment tested
- Nabiximols
What it measured
Main measures
The primary endpoint is the time to treatment failure in the randomised-withdrawal period.
Who could take part
MS (type not specified)
Inclusion: Subjects meeting the following criteria will be considered eligible for this study: Exclusion: The subject may not enter the study if ANY of the following apply:
As registered. Criteria can change, so ask the trial team or your neurologist.
About this trial
In the sponsor's words
To evaluate the maintenance of effect of GW-1000-02 [named Sativex® in Canada and also named Sativex® Oromucosal Spray] compared with placebo in relieving symptoms of spasticity due to MS, in subjects who have been receiving long-term benefit from GW-1000-02.
Loading reviews and guidelines…
Related trials
- ICE Trial
Phase 4 · Ongoing (inferred)
Still running
- A Study to Investigate Arbaclofen ER Tablets for the Trea…
Phase 3 · Not yet recruiting
Still running
- Cannabis (THC vs. CBD) in Multiple Sclerosis
Phase 2 · Recruiting
Still running
- ICE
Phase 4 · Recruiting
Still running
- Mechanisms of Cannabidiol in Persons With MS: the Role of…
Phase 2 · Recruiting
Still running
- AntibioBoNTA
Phase 3 · Ongoing
Still running
History
Started
Jun 2007
Assembled by software from public sources and not checked by people. Each record links to its source. Report an error